Filing Flows › Journey Medical (DERM) › Q2 2025
Journey Medical (DERM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Journey Medical (DERM) reported revenue of $15.0M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +14% from the quarter before. Operating margin was -19.2%, net loss $3.8M (25.3% of revenue).
Journey Medical, Q2 2025: revenue $15.0M (+1% year over year), operating margin -19.2%, net loss $3.8M, operating cash flow −$942K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.0M | +14% | +1% |
| Operating profit | −$2.9M | — | — |
| Net earnings | −$3.8M | — | — |
| Operating cash flow | −$942K | — | — |
What changed
Revenue was $15.0M in Q2 2025, up 1% year over year and up 14% from the previous quarter. Qbrexza was the largest line at 46% of revenue. Qbrexza added $113K year over year (up 2%), 73% of the total change. Accutane declined 41%.
Operating costs exceeded revenue by $2.9M, an operating margin of -19.2%. Total costs grew 1% against revenue growth of 1%. The fastest-growing cost line was SG&A (+15%). The quarter ended with a net loss of $3.8M, narrower than the previous quarter's $4.1M loss.
Operating cash flow was −$942K. Non-cash charges added back $1.3M of share-based compensation. Working capital and other items added $1.5M.
Questions
What was Journey Medical's revenue in the second quarter 2025?
Journey Medical (DERM) reported revenue of $15.0M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +14% from the quarter before.
Was Journey Medical profitable in the second quarter 2025?
Operating loss was $2.9M (-19.2% of revenue) and net loss $3.8M.
Source: Journey Medical 10-Q on SEC EDGAR.